PROJECT 12. Protocal Review

Markey癌症中心(MCC)方案审查和监测系统(PRMS)提供全面的 审查临床试验的科学有效性、可行性和在临床试验组合中的优先顺序 对科学进步的监测。PRMS必须在研究之前批准所有的介入癌症研究 启动，并有权建议关闭试验，因为缺乏科学进步或患者收益。 PRMS提供了一个框架，旨在平衡适当的资源利用，同时最大化 该地区现有和未来癌症患者参与临床试验的机会， 包括服务不足的肯塔基州阿巴拉契亚地区。新型MCC调查器的研制 临床试验和参与高优先级的国家试验提供了强大的治疗组合 可供MCC患者使用的研究。

The Markey Cancer Center (MCC) Protocol Review and Monitoring System (PRMS) provides thorough review of clinical trials for scientific validity, feasibility and prioritization within the clinical trials portfolio and monitoring of scientific progress. The PRMS must approve all interventional cancer research prior to study initiation and has the authority to recommend closure of trials for lack of scientific progress or patient accrual. The PRMS provides a framework which aims to balance appropriate resource utilization while maximizing the opportunities for current and future patients with cancer in this region to participate in clinical trials, including the underserved area of Appalachian Kentucky. The development of novel MCC investigator-initiated clinical trials and participation in high-priority national trials provide a robust portfolio of therapeutic research studies available to MCC patients.